Roche Vabysmo Sales Surpassed USD 4 Billion In 2024
Vabysmo Sales Accounts For More Than 35% Of Global Bispecific Antibodies Market Says Kuick Research
Delhi, Jan. 07, 2025 (GLOBE NEWSWIRE) — Global Bispecific Antibody Market, Drugs Sales, Patent, Price and Clinical Trials Insight 2029 Report Highlights:
- Bispecific Antibodies Development Proprietary Platforms Insight: > 30 Platforms
- Global Bispecific Antibodies Market Size Yearly and Quarterly Sales (2018 till 2024)
- Global Bispecific Antibodies Market Size 2024: > USD 8.5 Billion
- Global Bispecific Antibodies Market Forecast Till 2029
- Approved Bispecific Antibodies Yearly and Quarterly Sales (2018 till 2024)
- Approved Bispecific Antibodies Regional Sales (2018 till 2024)
- Clinical and Commercial Insight On Approved Bispecific Antibodies: 16 Antibodies
- Approved Bispecific Antibodies Pricing and Dosage Analysis
- Global Bispecific Antibodies Clinical Trials By Company, Indication and Phase: > 800 Antibodies
Download Report:
https://www.kuickresearch.com/report-bispecific-antibody-market-bispecific-antibodies-market
Vabysmo is emerging as a significant player in the pharmaceutical landscape, particularly within the ophthalmology sector. Developed by Roche, this bispecific antibody is approved for neovascular (wet) age-related macular degeneration, diabetic macular edema and retinal vein occlusion, which are some leading causes of blindness. Its unique mechanism of action, targeting both angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A), sets it apart from other therapies, offering a novel approach to managing these eye disorders.
The market response to Vabysmo has been robust and impressive. In 2023, Vabysmo’s global sales reached US$ 2.7 Billion, indicating strong market penetration and acceptance. This growing trajectory continued in 2024, as sales surged to US$ 3.2 Billion during first 9 months. This remarkable growth positions Vabysmo as the bispecific antibody with the fastest increasing sales in the market.
Vabysmo’s success has been attributed to a number of factors. First off, compared to medications that solely target VEGF or Ang-2, its dual-action mechanism offers a therapeutic benefit by treating two pathways implicated in the course of the disease, potentially improving clinical results. Second, patients and physicians find dose regimens convenient, as they can be less frequent than some current treatments. This enhances adherence and overall treatment satisfaction.
Geographically, the US remains the largest market for Vabysmo, driven by a substantial patient population, higher healthcare spending and robust insurance coverage for innovative therapies. Europe follows as the second largest market, with significant uptake in key countries like the UK, Germany and France, where aging population and high prevalence for retinal disorders contribute to the demand. Japan also represents a critical market, benefiting from the country’s advanced healthcare infrastructure and high awareness of retinal diseases.
Future developments involving growing indications, ongoing clinical trials, and possible label extensions will probably be crucial to Vabysmo’s sustained success. Furthermore, there appears to be a continuing need for efficient treatments given the rising incidence of age-related eye problems and diabetic retinopathy throughout the world. In the competitive biopharmaceutical industry, Roche’s strategic marketing initiatives and ongoing innovation will be essential to sustaining and possibly even accelerating Vabysmo’s growth trajectory.
In conclusion, Vabysmo’s rapid ascent in sales and market presence highlights its significant impact on the treatment landscape for retinal disorders. Its clinical efficacy, patient-centric dosing and expanding global footprint suggest a promising future for this bispecific antibody in addressing unmet needs in ophthalmology.
CONTACT: Neeraj Chawla Research Head Kuick Research neeraj@kuickresearch.com https://www.kuickresearch.com/
